Codexis Competitors

Codexis (NASDAQ:CDXS) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Codexis and Amgen's top-line revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codexis and Amgen's net margins, return on equity and return on assets.

Insider & Institutional Ownership

91.3% of Codexis shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codexis and Amgen, as reported by MarketBeat.com.

Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Amgen has a consensus price target of $261.0476, suggesting a potential upside of 2.32%. Given Codexis' stronger consensus rating and higher possible upside, research analysts plainly believe Codexis is more favorable than Amgen.

Summary

Amgen beats Codexis on 8 of the 14 factors compared between the two stocks.

Codexis (NASDAQ:CDXS) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Codexis and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codexis and Gilead Sciences' net margins, return on equity and return on assets.

Insider & Institutional Ownership

91.3% of Codexis shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codexis and Gilead Sciences, as reported by MarketBeat.com.

Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Gilead Sciences has a consensus price target of $97.92, suggesting a potential upside of 48.88%. Given Gilead Sciences' higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Codexis.

Summary

Gilead Sciences beats Codexis on 9 of the 14 factors compared between the two stocks.

Codexis (NASDAQ:CDXS) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Codexis and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codexis and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

91.3% of Codexis shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codexis and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Vertex Pharmaceuticals has a consensus price target of $293.1250, suggesting a potential upside of 32.58%. Given Vertex Pharmaceuticals' higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Codexis.

Summary

Vertex Pharmaceuticals beats Codexis on 11 of the 15 factors compared between the two stocks.

Codexis (NASDAQ:CDXS) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Codexis and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codexis and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

91.3% of Codexis shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codexis and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Regeneron Pharmaceuticals has a consensus price target of $646.2609, suggesting a potential upside of 30.65%. Given Regeneron Pharmaceuticals' higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Codexis.

Summary

Regeneron Pharmaceuticals beats Codexis on 11 of the 15 factors compared between the two stocks.

Codexis (NASDAQ:CDXS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Codexis and Biogen's top-line revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codexis and Biogen's net margins, return on equity and return on assets.

Insider & Institutional Ownership

91.3% of Codexis shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codexis and Biogen, as reported by MarketBeat.com.

Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Biogen has a consensus price target of $303.5862, suggesting a potential upside of 12.26%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Codexis.

Summary

Biogen beats Codexis on 9 of the 14 factors compared between the two stocks.

Codexis (NASDAQ:CDXS) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Insider & Institutional Ownership

91.3% of Codexis shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codexis and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Alexion Pharmaceuticals has a consensus price target of $153.8636, suggesting a potential downside of 2.33%. Given Codexis' stronger consensus rating and higher possible upside, research analysts plainly believe Codexis is more favorable than Alexion Pharmaceuticals.

Earnings & Valuation

This table compares Codexis and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codexis and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Codexis on 9 of the 14 factors compared between the two stocks.